Pulmonary Delivery of Liposomal Ciprofloxacin

Francis Dayton, David Cipolla, Igor Gonda, Paul Bruinenberg and James Blanchard

1Aradigm Corporation, Hayward, Ca 94545, USA  daytonf@aradigm.com


In recent years, there has been an increased interest in targeted drug delivery to the lungs, not only for local therapy but also for systemic therapy and for diagnostic purposes.

The duration of action of many inhaled drugs tends to be quite short, often requiring multiple dosing events throughout the day. We present data on a new liposomal formulation of ciprofloxacin (CFI) in development to manage respiratory infections, requiring just once-a-day dosing.


© Copyright Controlled Release Society  | Contact Us - Report a Bad Link |
Admin Access